Halifax, Nova Scotia –News Direct– MedMira Inc.
Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the appointment of Dr. Sam Ratnam as MedMira’s Director of Scientific & Regulatory Affairs and provides an update on its regulatory progress in the U.S. market.
U.S. Regulatory Update on COVID-19 Products
The recent announced recommendation by the U.S. FDA to IVD manufacturers to apply for the traditional regulatory path 510(k) approval outlines the continuous need for quality COVID-19 rapid test. While the Emergency Use Authorisation (EUA) is continuing, the regulators prepare for the future endemic situation and initiate the standard transition protocol for prevailing diseases. In contrary to the EUA application where manufacturer does not require to meet high quality standard, traditional approval process such as the 510(k) requires full compliance with the FDA Quality System Regulation (21 CFR Part 820). It is the most important mandate for all regulators including FDA and Health Canada to approve the highest quality product to serve the public need. Such requirements may include an existing FDA establishment license and the Medical Device Single Audit Program (MDSAP) certification. MedMira’s product lines REVEALCOVID-19® and VYRA™ have the data supporting such an application and can provide additional data if such may be required. At the same time, MedMira’s quality system has been certified for the MDSAP and the Company holds both the FDA and Health Canada establishment license for its North-American based facility. The Company continues with its dual strategy to receive the EUA(s) and the 510(k). This enables MedMira and its distributors to offer the highest regulatory approved products when available to market. While MedMira is in the EUA process, the Company is preparing the 510(k) pre-submission. MedMira will provide further updates on both applications when available.
U.S. Regulatory Update on Hepatitis C Product
The Company has previously announced the intention of seeking FDA approval for its Point of Care Reveal® Rapid Hepatitis C (HCV) Antibody Test. According to US Centers for Disease Control and Prevention (CDC), the incidence rate of acute hepatitis C in 2020 has more than doubled since 2013, a 124% increase. MedMira has taken immediate steps and a Q-submission (Q220148) was made to FDA and has received positive feedback. The submitted clinical and non-clinical protocols have been reviewed, and the Company has received clear instructions towards obtaining approval for this greatly demanded product in the USA and other parts of the world.
Growth of Scientific and Regulatory Support
MedMira has eight regulatory applications pending and is aiming to add three additional regulatory submission in the coming months to our three key markets. Therefore, the management has appointed Dr. Sam Ratnam as Director Scientific & Regulatory Affairs to support MedMira in its growth by introducing more products into the North-American and European markets.
Dr. Ratnam brings over 40 years of experience in public health, regulatory affairs and has been the principal in a number of important regulations set forward by the health authorities such as the guidelines on Syphilis, Hepatitis C and HPV. His invaluable expertise and intrinsic knowledge of the regulatory and clinical trial framework in Canada and the United States, will provide the Company even further momentum to push forward on its current and future applications.
Trademark REVEALCOVID-19®
MedMira is delighted to announce the receipt of the United States of America Trademark for its REVEALCOVID-19 brand. The trademark complements the MedMira’s portfolio of trademarked brands and further strengthen its uniqueness. Additional trademarks are currently in the final process which includes VYRA™ (Virus based antigen tests), BYRA™ (Bacteria based antigen/antibody tests) and PYRA™ (Parasite based antigen/antibody tests).
About Dr. Sam Ratnam
Dr. Sam Ratnam, MSc (Medical Microbiology; Madras), PhD (Medical Microbiology; Delhi), MPH (Johns Hopkins), FCCM (Fellow of Canadian College of Microbiologists), is Clinical Professor at Memorial University, St. John's, and Adjunct Professor, McGill University, Montreal, Canada. He was Director of Public Health Laboratory, Government of Newfoundland, St. John's, and served as Advisor to the National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, and Interim Advisor to the Public Health Laboratory, St. John's. He has served as chair or member of many Canadian federal and provincial advisory committees and working groups and as temporary advisor to the WHO. His research interests are clinical and public health microbiology with focus on STI diagnostics (200 scientific articles and abstracts).
Next Updates
MedMira will provide further updates on its CE and Health Canada progress in a separate announcement.
About MedMira
MedMira is a leading developer and manufacturer of Rapid Vertical Flow® diagnostics. The Company’s tests provide hospitals, labs, clinics and individuals with instant disease diagnosis, such as HIV, Syphilis, Hepatitis, and SARS-CoV-2, in just three easy steps. The Company’s tests are sold globally under the REVEAL®, REVEALCOVID-19®, Multiplo® and Miriad® brands. Based on its patented Rapid Vertical Flow® Technology, MedMira’s rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira’s corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit medmira.com. Follow us on Twitter and LinkedIn.
This news release contains forward‐looking statements, which involve risk and uncertainties and reflect the Company’s current expectation regarding future events, including statements regarding possible regulatory approval, product launch, future growth, and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
MedMira Inc.
Markus Meile
ir@medmira.com
https://medmira.com
View source version on newsdirect.com: https://newsdirect.com/news/medmira-provides-progress-update-236521963
Related Quotes
CGX Energy Inc. (TSXV: OYL) ("CGX") and Frontera Energy Corporation (TSX: FEC) ("Frontera"), joint venture partners (the "Joint Venture") in the Petroleum Prospecting License for the Corentyne block offshore Guyana, today announce that the parties have agreed to (i) extend the maturity date of the previously announced US$19 million convertible loan to CGX dated May 28, 2021, as amended (the "Loan Agreement") to November 30, 2022; and (ii) amend the previously announced amended Joint Operating Ag
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like…
DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI" or "the Trust") today announced that a wholly-owned subsidiary of DRI has acquired a royalty interest in Omidria from Omeros Corporation ("Omeros") for a purchase price of US$125 million.
Every investor in Northern Trust Corporation ( NASDAQ:NTRS ) should be aware of the most powerful shareholder groups…
Fox Factory Holding Corp. ( NASDAQ:FOXF ) shareholders might be concerned after seeing the share price drop 12% in the…
As the Federal Reserve raised interest rates to combat inflation, NorthCoast Asset Management found opportunity in bond ETFs during the third quarter. And although the firm remained cautious on stocks, it redeployed some of its cash positions in ETFs investing in equities. It favored ETFs buying and holding value stocks. "The opportunity cost of being in cash and not in…
It's easy to match the overall market return by buying an index fund. Active investors aim to buy stocks that vastly…
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put…
Google discontinued its Google Translate service in mainland China citing low usage, marking another retreat by the U.S. tech giant from the country.
Yahoo Finance Live anchor Seana Smith looks at several trending stocks in the after-hours trading session.
Over the weekend, the South American nation held the first round of its 2022 presidential election, and former President Luiz Inacio Lula da Silva was ahead in the polling — and investors are cheering. As of 10:45 a.m. ET Monday, shares of Brazilian oil giant Petroleo Brasileiro (NYSE: PBR) (NYSE: PBR.A) (aka Petrobras) were up 12.4%, while electric and gas utility Companhia Energetica de Minas Gerais (NYSE: CIG) had gained 14.6%, and water utility Companhia de Saneamento Basico do Estado de Sao Paulo (NYSE: SBS) (aka "Sabesp") was leading the whole Brazilian stock market higher with a 22.5% gain.
The catalyst that sent the electric vehicle (EV) maker plunging was quarterly vehicle deliveries that fell short of expectations. In a press release that dropped Sunday, Tesla revealed its third-quarter production and delivery numbers, and while the growth was robust, investors wanted more. In its press release, Tesla addressed the issue, saying, "Historically, our delivery volumes have skewed toward the end of each quarter … [but] as our production volumes continue to grow, it is becoming increasingly challenging to secure vehicle transportation capacity."
Shares of Boeing (NYSE: BA), which have trailed the broader market in recent months, were particularly strong on Monday, up more than 5% on a day when investors are shopping for potential bargains. Boeing shares have been hit particularly hard in recent months. In fact, Boeing announced a number of new jet orders during the period, a sign that demand is holding up.
Incumbent chip maker Intel (NASDAQ: INTC), a banner victim of this year's tech stock sell-off, had an unusually good Monday. The company's shares rose by almost 5% on the day, due in part to a general rebound of tech titles generally and chip makers specifically, and partly due to a looming divestment. After market hours on Friday, Intel's assisted- and autonomous-driving tech unit Mobileye filed a prospectus for an initial public offering (IPO).
Tesla shares are getting hammered after weaker-than-expected third-quarter delivery numbers. The reason isn't 'cars in transit.'
The stock market is often a game in reverse psychology. That is, when the mood gets too euphoric, it’s often a sign it is time to sell. Likewise, when sentiment hits the skids, that could be the ultimate signal the time is right to load up the truck. And on that subject, J.P. Morgan’s Marko Kolanovic thinks we are at – or at least near – the bottom. The firm’s global market strategist believes the Fed’s hawkish stance has left stocks “very oversold,” and while inflation remains persistently high
Berkshire Hathaway Vice Chairman Greg Abel, the likely successor to CEO Warren Buffett, bought about $68 million of the company’s shares last Thursday in what appears to be his first purchases of Berkshire stock since he assumed the position in 2018. In several Form 4 filings Monday with the Securities and Exchange Commission, Abel disclosed that he purchased 168 Berkshire Hathaway (ticker: BRK/A, BRK/B) Class A shares through the Gregory Abel Revocable Trust on behalf of his wife, children, and other family members. Abel paid in a range of roughly $405,000 to $408,000 per class A share for the Berkshire stock, which closed Monday at $413,300, up 1.7% on the session.
Recently, Zacks.com users have been paying close attention to Medical Properties (MPW). This makes it worthwhile to examine what the stock has in store.
Reinvesting all the dividend payouts you receive from this stock could double your initial investment in four short years.
Third-quarter data from automakers is beginning to trickle in, and EV adoption seems to be as strong as has been expected.